- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03826524
Epinephrine Dose: Optimal Versus Standard Evaluation Trial (EpiDOSE)
CanROC Epinephrine Dose: Optimal Versus Standard Evaluation Trial (CanROC EpiDOSE Trial)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is designed as a prospective, multicentre, single-blinded randomized controlled trial (RCT) where eligible OHCA patients are randomized to receive a low cumulative dose of epinephrine (low dose epinephrine, up to 2mg total) or a standard cumulative dose of epinephrine (standard dose epinephrine, up to 6mg total) in a 1:1 fashion.
Eligible OHCA patients will be treated by emergency medical service (EMS) providers who will initiate cardiopulmonary resuscitation (CPR) and the delivery of defibrillation shocks per EMS treatment protocols. After one defibrillation and when feasible, EMS providers will establish peripheral intravenous (IV) access, and patients will be randomly allocated to 1 of the 2 study arms. Subsequent study drug doses will be administered every 3-5 minutes, based on current guidelines and paramedic protocols, during resuscitation until the first return of spontaneous circulation (ROSC) is achieved or if resuscitation has been terminated by the base hospital physician. Other medications (e.g. antiarrhythmics, magnesium, beta blockers) and interventions (e.g. intubation) may be interposed as required. Follow-up will take place using a combination of administrative databases (e.g. the Discharge Abstract Database and the National Ambulatory Care Reporting System) and telephone interviews.
This RCT will evaluate a fundamental change in the treatment of OHCA. The investigators hypothesize that a low cumulative dose of epinephrine will improve patient survival to hospital discharge compared to a standard cumulative dose of epinephrine.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Theresa Aves, MSc
- Phone Number: 46787 416-864-6060
- Email: theresa.aves@unityhealth.to
Study Locations
-
-
Ontario
-
Halton, Ontario, Canada
- Recruiting
- Halton Region Paramedic Services
-
Contact:
- Theresa Aves
- Phone Number: 46787 416-864-6060
-
Principal Investigator:
- Sheldon Cheskes, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Out-of-hospital cardiac arrest treated by paramedics
- Initial recorded cardiac rhythm of VF or pulseless VT, or, AED shock on first analysis administered or witnessed by EMS (paramedic or fire)
- Established intravenous vascular access
Exclusion Criteria:
- Known or apparent age <18 years
- Initial recorded cardiac rhythm of pulseless electrical activity or asystole
- Cardiac arrest due to an obvious non-cardiac primary cause (e.g. blunt or penetrating trauma, exsanguination, burns, drug overdose, drowning, anaphylaxis, sudden asphyxiation, etc.)
- Prisoners or persons in police custody
- Known allergy or sensitivity to epinephrine
- Prior receipt of non-study kit intravenous, intraosseous, or intramuscular epinephrine during resuscitation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Low Dose Epinephrine
Epinephrine up to 2mg total
|
Epinephrine 1mg 1:10000 (10cc) per dose
Other Names:
|
Active Comparator: Standard Dose Epinephrine
Epinephrine up to 6mg total
|
Epinephrine 1mg 1:10000 (10cc) per dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival to hospital discharge
Time Frame: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital
|
Through study completion (up to 5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Return of spontaneous circulation in out-of-hospital setting
Time Frame: Through study completion (up to 5 years)
|
Return of spontaneous circulation in the field
|
Through study completion (up to 5 years)
|
Survival to emergency department arrival
Time Frame: Through study completion (up to 5 years)
|
Individuals alive upon arrival to a hospital emergency department
|
Through study completion (up to 5 years)
|
Survival to admission with death prior to discharge
Time Frame: Through study completion (up to 5 years)
|
Individuals alive upon hospital admission who die in-hospital before being discharged
|
Through study completion (up to 5 years)
|
Survival to discharge outside of a long-term healthcare facility e.g. nursing home
Time Frame: Through study completion (up to 5 years)
|
Individuals discharged alive from hospital to a care facility
|
Through study completion (up to 5 years)
|
Modified Rankin Scale (mRS) score
Time Frame: 12+/-3 months
|
Assessment of neurological function, scores range from 0 to 6 where higher scores indicate worse neurological function (0=no symptoms, 6=dead)
|
12+/-3 months
|
Health Utility Index-3 (HUI-3) score
Time Frame: 12+/-3 months
|
Assessment of quality of life, scores range from -0.36 to 1 where higher scores indicate better quality life (negative scores=a state worse than being dead, 0=dead, 1=perfect health)
|
12+/-3 months
|
Hospital Anxiety and Depression Scale score
Time Frame: 12+/-3 months
|
Assessment of quality of life, scores range from 0 to 21 where higher scores indicate more anxiety/depression
|
12+/-3 months
|
Length of stay in hospital
Time Frame: Through study completion (up to 5 years)
|
Length of time an individual remained in-hospital (length in days)
|
Through study completion (up to 5 years)
|
Length of stay in critical care unit
Time Frame: Through study completion (up to 5 years)
|
Length of time an individual remained in a crucial care unit (length in days)
|
Through study completion (up to 5 years)
|
Survival post-arrest
Time Frame: Up to 5 years
|
Survival following hospital discharge, up to 5 years
|
Up to 5 years
|
Recurrent cardiac arrest(s)
Time Frame: Up to 5 years
|
Number of cardiac arrests following the index arrest
|
Up to 5 years
|
ICD implant post-arrest
Time Frame: Up to 5 years
|
Whether an implantable cardioverter defibrillator was implanted post-arrest
|
Up to 5 years
|
Cardiovascular re-hospitalization(s)
Time Frame: Up to 5 years
|
Number of cardiovascular re-hospitalizations
|
Up to 5 years
|
All-cause re-hospitalizations(s)
Time Frame: Up to 5 years
|
Number of re-hospitalizations for any reason
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Dorian, MD, MSc, Unity Health Toronto
- Principal Investigator: Steve Lin, MD, MSc, Unity Health Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Death, Sudden
- Arrhythmias, Cardiac
- Cardiac Conduction System Disease
- Death
- Heart Arrest
- Ventricular Fibrillation
- Tachycardia
- Tachycardia, Ventricular
- Out-of-Hospital Cardiac Arrest
- Death, Sudden, Cardiac
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Epinephrine
Other Study ID Numbers
- EpiDOSE Protocol Version 2.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Fibrillation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationShort-coupled Idiopathic Ventricular FibrillationNetherlands
-
Guidant CorporationBoston Scientific CorporationCompletedHeart Failure | Ventricular Tachycardia, Ventricular FibrillationIsrael, Denmark
-
Boston Scientific CorporationCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular TachycardiaUnited States, Netherlands
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Italy, Israel
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Belgium, Italy
-
Mayo ClinicMedtronicCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Supraventricular TachycardiaUnited States, Israel
-
Institute for Clinical and Experimental MedicineRecruitingAtrial Fibrillation | Acute Heart Failure | Left Ventricular Dysfunction | Atrial Fibrillation RapidCzechia
-
University of Turin, ItalyUniversity of Padova; Centro Cardiologico Monzino; Policlinico Casilino ASL RMB; Humanitas Research Hospital IRCCS, Rozzano-MilanUnknownPersistent Atrial Fibrillation | Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction
-
Abbott Medical DevicesCompletedVentricular Tachycardia | Persistent Atrial FibrillationCanada, South Africa, Denmark, Australia, Italy, Austria, France, Germany, Netherlands, Portugal, Spain
-
Ottawa Heart Institute Research CorporationNot yet recruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
Clinical Trials on Epinephrine
-
Tel Aviv UniversitySheba Medical Center; Private practice, Dr. Malka AshkenaziUnknown
-
Seoul Medical CenterCompletedSpinal Anesthesia | Total Knee Replacement ArthroplastyKorea, Republic of
-
Amphastar Pharmaceuticals, Inc.CompletedAsthma | Shortness of Breath | Wheezing | BronchospasmUnited States
-
Seoul Medical CenterCompleted
-
Amphastar Pharmaceuticals, Inc.Terminated
-
Dr. Aayush Khanal, MDCompleted
-
De Motu CordisNovotech (Australia) Pty LimitedCompletedAnaphylactic ReactionAustralia
-
Amphastar Pharmaceuticals, Inc.Completed
-
Boston Children's HospitalEnrolling by invitationHypotensionUnited States